FDA Lifts Restrictions on Rosiglitazone

• Autores: Diane S. Aschenbrenner
• Localización: American Journal of Nursing, ISSN 0002-936X, Vol. 114, Nº. 4, 2014, págs. 24-25
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • * The Food and Drug Administration has lifted many of the restrictions it had placed on the type 2 antidiabetic drug rosiglitazone (Avandia) in 2011.

    * Reevaluation of data from a major clinical trial indicated that rosiglitazone did not increase the risk of cardiovascular events as had been previously suggested.